News and press releases
Stay up to date with the Association’s news and events.
Quick links
Press Releases
PPTA Statements
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Jul 21, 2005
Statement on Update on Safety of Albumin
The Plasma Protein Therapeutics Association (PPTA) appreciates actions taken by the FDA and the Blood Products Advisory Committee (BPAC) with respect to the safety of albumin.
All
PPTA statements
Jul 21, 2005
Statement on Update on Safety of Albumin
The Plasma Protein Therapeutics Association (PPTA) appreciates actions taken by the FDA and the Blood Products Advisory Committee (BPAC) with respect to the safety of albumin.
All
PPTA statements
Oct 21, 2004
PPTA Statement on Review of Donor Weight Loss Monitoring
The Plasma Protein Therapeutics Association (PPTA) is the international trade association and standards-setting organization for the world's major producers of plasma-derived and recombinant analog therapies.
All
PPTA statements
Oct 21, 2004
PPTA Statement on Review of Donor Weight Loss Monitoring
The Plasma Protein Therapeutics Association (PPTA) is the international trade association and standards-setting organization for the world's major producers of plasma-derived and recombinant analog therapies.
All
PPTA statements
Jul 22, 2004
PPTA Statement on Review of Donor Blood Pressure Requirements
The Plasma Protein Therapeutics Association (PPTA) is the international trade association and standards-setting organization for the world’s major producers of plasma-derived and recombinant analog therapies.
All
PPTA statements
Jul 22, 2004
PPTA Statement on Review of Donor Blood Pressure Requirements
The Plasma Protein Therapeutics Association (PPTA) is the international trade association and standards-setting organization for the world’s major producers of plasma-derived and recombinant analog therapies.
All
PPTA statements
PPTA Statement on the Revision of the General EU Pharmaceutical Legislation
PPTA welcomes the revision of the EU pharmaceutical legislation as an opportunity to improve access to therapies, including life-saving plasma-derived medicinal products (PDMPs) for EU patients. A revised framework has the potential to provide a robust set of provisions that will continue to ensure the safety and quality of human plasma used for manufacturing, while upholding the safety, quality, and efficacy of PDMPs.
All
PPTA statements
PPTA Statement on the Revision of the General EU Pharmaceutical Legislation
PPTA welcomes the revision of the EU pharmaceutical legislation as an opportunity to improve access to therapies, including life-saving plasma-derived medicinal products (PDMPs) for EU patients. A revised framework has the potential to provide a robust set of provisions that will continue to ensure the safety and quality of human plasma used for manufacturing, while upholding the safety, quality, and efficacy of PDMPs.
All
PPTA statements
No results found